AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain.
The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers.
It is also involved in developing various research programs for other neurological diseases.
The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University.
Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Country | United States |
IPO Date | Dec 23, 2020 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 8 |
CEO | Dr. Milton H. Werner Ph.D. |
Contact Details
Address: 3350 Riverwood Parkway SE Atlanta, Georgia United States | |
Website | https://www.inhibikase.com |
Stock Details
Ticker Symbol | IKT |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001750149 |
CUSIP Number | 45719W106 |
ISIN Number | US45719W2052 |
Employer ID | 00-0000000 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Charles Warren Olanow B.Sc., F.R.C.P.C., M.D. | Chief Executive Officer of Clintrex Research Corporation & Member of Scientific Advisory Board |
Dr. Milton H. Werner Ph.D. | Chief Executive Officer, President & Director |
Garth Lees-Rolfe CPA | Chief Financial Officer |
Dan Williams | Controller |
Dr. Surendra Singh | Head of Chemistry, Manufacturing & Controls |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 05, 2024 | 8-K | Current Report |
Dec 05, 2024 | 424B3 | Filing |
Dec 03, 2024 | S-3/A | [Amend] Filing |
Nov 18, 2024 | S-3 | Filing |
Nov 18, 2024 | DEF 14A | Filing |
Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Nov 14, 2024 | 10-Q | Quarterly Report |
Nov 08, 2024 | PRE 14A | Filing |
Oct 28, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
Oct 28, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |